The vaccine for Haemophilus influenzae type b is called a conjugate vaccine. It is composed of the tetanus toxoid protein conjugated tothe capsular polysaccharide of the H. influenzae type b bacteria. When used to vaccinate infants, the antibody response generated bythis vaccine would include0 0 0 0antibodies that bind only to the protein-polysaccharide conjugate in the vaccine.antibodies to the tetanus toxoid only.antibodies to the bacterial polysaccharide and the tetanus toxoid.antibodies to the bacterial polysaccharide only.

The Hib conjugate vaccine is designed to provide immunity against infections caused by the bacterium Haemophilus influenzae type b, which couses diseases such as meningitis and pneumonia in young children.The correct option is:antibodies to the bacterial polysaccharide and the tetanus toxoid.Explanation:Conjugate Vaccine Composition:The Haemophilus influenzae type b (Hib) conjugate vaccine is composed of the capsular polysaccharide of H. influenzae type b conjugated to the tetanus toxoid protein.Immune Response Mechanism:The conjugation of the bacterial polysaccharide to a protein carrier (tetanus toxoid) enhances the immune response, especially in infants. The protein carrier acts as a T-cell-dependent antigen, leading to a more robust and effective immune response.Antibody Production:Vaccination with this conjugate vaccine stimulates the production of antibodies against both the bacterial polysaccharide (from H. influenzae type b) and the tetanus toxoid.Dual Protection:Antibodies against the bacterial polysaccharide provide protection against Haemophilus influenzae type b infections.Antibodies against the tetanus toxoid contribute to protection against tetanus.Enhanced Effectiveness:Conjugate vaccines are particularly effective in infants and young children because they overcome the limitations of the immature immune system, which may not respond well to polysaccharide antigens alone.Therefore, the vaccination results in the generation of antibodies to both the bacterial polysaccharide and the tetanus toxoid, offering dual protection against Hib infections and tetanus.